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Abstract
The fibroblast growth factor receptor 2 (FGFR2) locus is consistently the top hit in genome-wide association studies for 
oestrogen receptor-positive (ER+) breast cancer. Yet, its mode of action continues to be controversial. Here, we employ a 
systems biology approach to demonstrate that signalling via FGFR2 counteracts cell activation by oestrogen. In the presence 
of oestrogen, the oestrogen receptor (ESR1) regulon (set of ESR1 target genes) is in an active state. However, signalling by FGFR2 
is able to reverse the activity of the ESR1 regulon. This effect is seen in multiple distinct FGFR2 signalling model systems, 
across multiple cells lines and is dependent on the presence of FGFR2. Increased oestrogen exposure has long been associated 
with an increased risk of breast cancer. We therefore hypothesized that risk variants should reduce FGFR2 expression and 
subsequent signalling. Indeed, transient transfection experiments assaying the three independent variants of the FGFR2 
risk locus (rs2981578, rs35054928 and rs45631563) in their normal chromosomal context show that these single-nucleotide 
polymorphisms (SNPs) map to transcriptional silencer elements and that, compared with wild type, the risk alleles augment 
silencer activity. The presence of risk variants results in lower FGFR2 expression and increased oestrogen responsiveness. 
We thus propose a molecular mechanism by which FGFR2 can confer increased breast cancer risk that is consistent with 
oestrogen exposure as a major driver of breast cancer risk. Our findings may have implications for the clinical use of FGFR2 
inhibitors.
Introduction
Breast cancer continues to be the most frequently diagnosed 
cancer globally and the leading cause of cancer death among 
females (1). The genetic factors contributing to breast cancer 
have been studied in some detail: rare genetic variants with 
high penetrance such as mutations in the BRCA1/2 genes give 
rise to a 50–80% lifetime risk of developing breast cancer, but 
these rare mutations only account for ~5–7% of the total inci-
dence of breast cancers (2). Genome-wide association studies 
have examined the common genetic variation in the population 
that is associated with breast cancer and have repeatedly iden-
tified fibroblast growth factor receptor 2 (FGFR2) as their ‘top 
hit’ (3–11), with the risk variants conferring increased risk for 
oestrogen receptor-positive (ER+) disease. Due to the common 
nature of the risk alleles at this locus, it is believed that the locus 
contributes to up to 16% of all breast cancers (4,12), suggesting a 
significant disease burden due to FGFR2.
The functional role of FGFR2 in the breast appears to depend 
on the cellular context and developmental stage. Experimental 
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data obtained in mice show that FGFR2 is pro-proliferative in 
early mammary gland development, and reduced expression is 
associated with developmental defects in branching morpho-
genesis (13–16). In another study, low expression of FGFR2 was 
associated with lower numbers of breast tumour-initiating cells 
(17). However, in microdissected breast tumours FGFR2 mRNA 
and protein levels were reduced in tumour cells in comparison 
with paired normal breast epithelium, suggesting that tumouri-
genesis is associated with reduced FGFR2 expression (18). Thus, 
the molecular mechanism by which the FGFR2 protein contrib-
utes to tumourigenesis is not fully understood.
Genetic mapping studies of the FGFR2 risk locus have led 
to the identification of three independent functional variants 
[independent, correlated highly associated variants] (19,20). 
Chromatin conformation studies have demonstrated that 
sequences around the risk single-nucleotide polymorphisms 
(SNPs) interact with the FGFR2 promoter, making this the likely 
target gene. However, the effect of the risk variants on FGFR2 
expression has remained controversial (20–23).
In this study, we examine the effect of FGFR2 activation on 
the transcriptional profiles of ER+ breast cancer cell lines. In 
vitro, FGFR2 can be activated by a number of different fibroblast 
growth factors (FGFs), although FGF10, a mesenchymal to epi-
thelial signalling molecule, is the most potent agonist of FGFR2 
and is the relevant FGFR2 ligand for breast epithelial cells (24,25). 
Here, we examine FGFR2 activation either by FGF10 stimulation 
or by small-molecule activators and consistently observe that 
FGFR2 signalling counteracts cell activation by oestrogen signal-
ling. In keeping with this observation, we find that in transient 
transfection assays all three independent risk SNPs reduce tran-
scriptional activation from the FGFR2 promoter. Our findings 
suggest that reduced FGFR2 expression and signalling is associ-
ated with an increase in ER+ breast cancer risk. 
Materials and methods
Cell culture
Michigan Cancer Foundation-7 (MCF-7) human breast cancer cells were 
cultured in Dulbecco’s modified Eagle’s medium (Invitrogen) supple-
mented with 10% fetal bovine serum (FBS) and antibiotics. ZR751, T47D 
and BT474 human breast cancer cells were cultured in RPMI (Invitrogen) 
supplemented with 10% FBS and antibiotics. SUM52PE human breast can-
cer cells were cultured in Ham/F-12 (Invitrogen) supplemented with 10% 
FBS, 5 µg/ml insulin, 1 µg/ml hydrocortisone and antibiotics. All cells were 
maintained at 37°C, 5% CO2. All cell lines were from the CRUK Cambridge 
Institute biorepository collection. Cell lines were authenticated by short 
tandem repeat genotyping using the GenePrint 10 (Promega) system and 
confirmed to be mycoplasma free. Cell line stocks were tested in September 
and October 2013, 2 months prior to microarray hybridization. Frozen ali-
quots were stored and after thawing not cultured for longer than 6 months.
Stimulation of FGFR2 signalling
Cells were plated at 5 × 105 cells/well in six-well dishes and left in com-
plete medium overnight. Cell synchronization via oestrogen-starvation 
was then carried out for 3 days in oestrogen-free media (phenol red-free 
media supplemented with 5% charcoal dextran-treated FBS and 2 mM 
l-glutamine), with media changes every 24 h. Oestrogen-deprived cells 
were stimulated with 1 nM β-estradiol (E2; Sigma) or 100 ng/ml FGF10 
(Invitrogen) in combination with 1 nM E2, for 6 or 24 h.
RNA collection and microarray processing
Total RNA was extracted from cells using the miRNeasy Mini Kit (QIAGEN) 
and quality checked using an RNA 6000 Nano Chip on a 2100 Bioanalyser 
(Agilent). RNA (250 ng; RNA integrity number > 9) was used for cRNA ampli-
fication and labelling using the Illumina TotalPrep-96 kit (Ambion). cRNA 
was hybridized to HumanHT-12 v4 Expression BeadChips according to the 
manufacturer’s protocol (Illumina WGGX DirectHyb Assay Guide 11286331 
RevA). Bead level data were preprocessed to remove spatial artefacts, log2-
transformed and quantile normalized using the beadarray package (26) 
from Bioconductor. The full microarray data sets have been deposited in 
Gene Expression Omnibus (GEO) under the SuperSeries number GSE74663.
Quantitative RT-PCR
One microgram of total RNA was reverse transcribed using the High 
Capacity cDNA Reverse Transcription Kit (Applied Biosystems) and qRT-
PCR performed using cDNA obtained from 10 ng of total RNA.  qRT-PCR 
was performed using an ABI 9800HT Sequence Detection System (Applied 
Biosystems) with SDS software version 2.3. All primers are listed in 
Supplementary Table  1, available at Carcinogenesis Online. Amplification 
and detection were carried out in 384-well Optical Reaction Plates (Applied 
Biosystems) with Power SYBR Green Fast 2x qRT-PCR Mastermix (Applied 
Biosystems). All expression data were normalized to DGUOK expression. 
Primer-specificity was confirmed at the end of each qRT-PCR run through 
the generation of single peaks in melt-curve analysis. Data analysis was 
performed using the 2−ΔΔCT method (27). RNA from HMF3S cells was a kind 
gift from Dr M.Hoare at the CRUK Cambridge Institute.
Western immunoblotting
Cells were grown in 10 cm Petri dishes, washed in phosphate-buffered 
saline and lysed on ice in RIPA buffer with cOmplete Mini ethylenediami-
netetraacetic acid-free protease inhibitor cocktail (Roche). Resulting cell 
lysates were passed through a fine-gauge syringe needle several times, 
centrifuged at 10 000g for 1 min and left at −80°C at least overnight. Protein 
samples were separated by sodium dodecyl sulphate–polyacrylamide gel 
electrophoresis using 4–12% Bis–Tris gels (Novex) for 2.5 h (30 min at 60 V, 
120 min at 120 V) and transferred by electrophoresis using an iBlot (Novex) 
for 7–8 min onto a nitrocellulose membrane (iBlot Gel Transfer Stacks; 
Novex). Successful transfer of protein was confirmed using Ponceau S 
Solution (Sigma). Membranes were ‘blocked’ at room temperature for 1 h 
with 5% (wt/vol) dried milk in Tris-buffered saline (TBS) with 0.1% Tween-
20 (TTBS), washed 3× with TTBS and probed with the relevant primary 
antibody (anti-FGFR2, 1:200, Santa Cruz sc-122; anti-FGFR1, 1:1000, Santa 
Cruz sc-121; anti-ESR1, 1:5000, Santa Cruz sc-543 X; anti-β-actin, 1:5000, 
Cell Signalling) in blocking solution at 4°C overnight. Membranes were 
then rewashed with TTBS 3× and incubated with appropriate horserad-
ish peroxidase-conjugated secondary antibody (1:10 000, Amersham). 
Following further washing with TTBS, blots were treated with SuperSignal 
West Chemiluminescent Substrate (Thermo Scientific) and immunoreac-
tive proteins detected by exposure to film (FUJIFILM). In all cases, loading 
controls of β-actin were run in parallel.
Molecular cloning
The full-length FGFR2 promoter was amplified from total genomic 
DNA from MCF-7 human breast cancer cells using primers 1 and 2 
(Supplementary Table 2, available at Carcinogenesis Online). The PCR prod-
uct was cloned into the pGL3-Basic Luciferase Reporter Vector (Promega), 
following XhoI/HindIII digestion, to generate a reporter construct in which 
the luciferase gene is transcribed from the FGFR2 promoter. Reporter plas-
mids containing the putative FGFR2 regulatory elements were generated by 
cloning ~800 bp fragments, overlapping the FGFR2 risk variants, upstream 
of the FGFR2 promoter, following SacI/XhoI digestion. The 801 bp regula-
tory element (RE1) containing the rs2981578 and rs35054928 SNPs was 
amplified from total genomic DNA from T47D (non-risk variants; T/-) and 
ZR751 (risk variants; C/C) human breast cancer cells using primers 3 and 
Abbreviations 
ER oestrogen receptor
FBS fetal bovine serum
FGFR fibroblast growth factor receptor
GSEA gene set enrichment analysis
SNP single-nucleotide polymorphism
TBS Tris-buffered saline
TSS transcription start sites 
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4 (Supplementary Table 2, available at Carcinogenesis Online). Site-directed 
mutagenesis was performed on the ‘non-risk’ and ‘risk’ reporter plasmids 
using the QuikChange II XL Site-Directed Mutagenesis Kit (Agilent) to gen-
erate constructs with single SNPs (T/C and C/-). The 839 bp regulatory ele-
ment (RE2) containing the rs45631563 risk variant (A) was amplified from 
T47D genomic DNA using primers 5 and 6 (Supplementary Table 2, avail-
able at Carcinogenesis Online). Site-directed mutagenesis was performed 
on the ‘risk’ rs45631563 reporter plasmid using the QuikChange II XL Site-
Directed Mutagenesis Kit (Agilent) to generate a construct containing the 
non-risk SNP variant of rs45631563 (T). The orientation and sequence of 
all cloned plasmids were confirmed by DNA sequencing (GATC Biotech).
Luciferase reporter assay
MCF-7 cells were plated at 0.5 × 105 cells/well in 24-well dishes and left 
in complete medium until 50–70% confluent. Cells were transfected 
with luciferase and β-galactosidase constructs at a concentration of 0.5 
and 0.1 µg per well, respectively, using FuGENE HD Transfection Reagent 
(Promega), according to manufacturer’s protocol. After 24 h, cells were lysed 
with Reporter Lysis Buffer (Promega) and luciferase and β-galactosidase 
assays were performed on a PHERAstar FS Microplate Reader (BMG 
LABTECH) using the appropriate assay kits (Promega), according to manu-
facturer’s protocol. Transfection of each reporter construct was performed 
in triplicate in each assay and a total of three assays were performed on 
three separate days.
Transient transfection of siRNA
MCF-7 cells were transfected with ON-TARGETplus SMARTpool siRNA 
(Dharmacon) directed against FGFR2 (L-003132-00), ESR1 (L-003401-00) and 
a control non-targeting pool (D-001810-01) using Lipofectamine RNAiMax 
Reagent (Invitrogen), according to manufacturer’s protocol. Following 
addition of the transfection complexes, cells were incubated overnight 
before cell synchronization via oestrogen-starvation and stimulation of 
oestrogen/FGFR2 signalling was performed.
Chromatin immunoprecipitation
For ESR1 ChIP-seq, cells were oestrogen starved for three consecutive 
days and E2-stimulated for 45 min. ChIP-seq was performed as previously 
described (28). Briefly, cells were cross-linked in 1% formaldehyde for 
10 min. Nuclear extracts were prepared and sonicated using a Bioruptor 
(Diagenode) for 15 min on the ‘high’ setting with cycles of 30 s on and 30 s 
off. Sonicated lysate was mixed with Protein A  Dynabeads (Invitrogen) 
pre-incubated with antibody against ESR1 (Santa Cruz sc-543 X; 10  µg 
of antibody in 50  µl volume, diluted 1:25 in sonicated nuclear extract). 
Immunoprecipitated chromatin was used to prepare Solexa sequencing 
libraries. The full ChIP-seq data set has been deposited in GEO under the 
accession code GSE48930.
Analysis of gene expression data
The Bioconductor package ‘limma’ (29) was used to call differentially 
expressed genes, and the log fold change metric was used to obtain the 
ranked phenotypes required for the gene set enrichment analysis (GSEA).
Computation and validation of the ESR1 regulon
As previously described (30), we used mutual information in gene 
expression data [METABRIC data sets (31)] to calculate a regulatory net-
work in which ESR1 is linked to all its potential target genes. We refer to 
these target genes as the ESR1 regulon. The network can be simplified or 
‘filtered’ by applying the data processing inequality (dpi) function with 
increasingly stringent thresholds so that targets assigned to ESR1 are 
more likely to be direct targets. Validation of the regulon was carried 
out by testing whether ESR1 binding sites derived from ChIP-seq data 
in MCF-7 breast cancer cells are enriched near target genes. Distances 
between the nearest ESR1 binding site and the transcription start sites 
(TSS) were calculated and binned over a regular grid of 512 points by the 
‘density’ function in ‘R’ to compute the kernel density estimates. Binding 
site density is given as the estimated number of sites in each point as 
a fraction of all TSS in the regulon. Statistical significance of the enrich-
ment was assessed by comparison with random regulons or random 
genomic positions.
Two-tailed GSEA
GSEA (32) assesses the skewed distribution of a selected gene set (S), 
here the ESR1 regulon, in a list of genes (L) ranked by a particular phe-
notype, in this case the gene expression response to stimulation by E2, 
E2 + FGF10 or siESR1 treatment. The two-tailed GSEA method is based on 
the Connectivity Map procedure (33). The regulon is split into two sub-
groups, positive targets (A) and negative targets (B), using Pearson’s corre-
lation, whereas genes in the phenotype are ranked using the differentially 
expressed signatures (i.e. top-down phenotype). The distribution of A and 
B are then tested by the GSEA statistics in the ranked phenotype, produc-
ing independent enrichment scores (ES) for each subgroup. A good sepa-
ration of the two distributions and maximum deviation from zero near 
opposite extremes is required for a clear association. Therefore, an addi-
tional step is executed testing the differential enrichment. The two-tailed 
GSEA was performed in ‘R’ using the function ‘tni.gsea2’ in the ‘RTN’ pack-
age (30,34) with 1000 permutations.
Motif discovery
The HOMER motif discovery algorithm (findMotifsGenome.pl v4.7) was 
used to identify either known or novel transcription factor binding motifs 
(scripts to reproduce this analysis are provided as Supplementary Material, 
available at Carcinogenesis Online). We varied the dpi threshold to define 
the positive and negative targets within the ESR1 regulon. The derived 
gene lists are given in Supplementary Table 3, available at Carcinogenesis 
Online. The ‘R’ (v3.2.3) package TxDb.Hsapiens.UCSC.hg18.knownGenes 
(v3.2.2) was used to find ESR1 ChIP-seq binding peaks (GSE25710) within 
a symmetric 200 or 250 kb window, centred on the gene TSS of the ESR1 
regulon genes (hg18/NCBI36). These peaks were used as the search space 
for the motif finding algorithm. A more stringent dpi threshold or smaller 
window around the TSS generated similar results, albeit with less signifi-
cant P-values.
Additional information
Microarray data have been deposited in GEO under the SuperSeries num-
ber GSE74663 and the ‘R’ code that reproduces the results presented in 
this study is available in Bioconductor (http://bioconductor.org/packages/
RTN/). The scripts used to reproduce the motif finding analysis are pro-
vided as Supplementary Material, available at Carcinogenesis Online. ChIP-
seq data have been deposited in GEO under accession code GSE48930.
Results
FGFR2 signalling suppresses ESR1 signalling in ER+ 
breast cancer cells
Epidemiologic studies have shown that FGFR2 confers risk for 
ER+ disease only (3–11,35–37). We therefore employed oestrogen-
dependent cell lines to examine the effect of FGFR2 activation 
using a systems biology approach.
Based on gene expression profiles in 2000 breast cancers, 
our previous network analysis (30) using ARACNe (38) defined 
a regulon (set of potential target genes) for ESR1. This algo-
rithm infers target genes based on mutual information and 
tests for significance via permutation and bootstrap analysis. 
The inferred targets can be direct or indirect. To remove indirect 
targets, we applied a dpi step in which increasingly stringent 
thresholds were set. We then asked whether the genes in the 
more stringently defined regulon display greater ESR1 binding, 
as assayed by ESR1 ChIP-seq. There was a significant enrichment 
when the ESR1 regulon was compared with random regulons or 
to random genomic sites (Supplementary Figure 1, available at 
Carcinogenesis Online). ESR1 binding density increased when the 
more stringently defined regulons were tested, and all the sub-
sequent analysis used this filtered regulon.
We first characterized the behaviour of the ESR1 regulon in 
MCF-7 cells. We examined the effect of oestrogen stimulation 
and compared the resultant gene expression profile with that of 
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unstimulated cells. ‘Limma’ analysis revealed a similar number 
of activated and repressed genes. In an analysis of the ESR1 reg-
ulon as a whole, the opposing effects of these two gene sets may 
obscure each other. We therefore split the regulon into a group of 
activated and a group of repressed genes, based on the Pearson’s 
correlation of gene expression between ESR1 and each target in 
tumours (31). A negative value indicates a repressed target gene 
and a positive value indicates an activated target gene. We then 
asked how the two sets are distributed in a ranked list of oes-
trogen-responsive genes using two-tailed GSEA. The two-tailed 
GSEA tests whether positive or negative targets for a transcrip-
tion factor of interest are enriched at each extreme of a par-
ticular response (e.g. oestrogen stimulation). As expected, GSEA 
revealed that oestrogen stimulation upregulates genes that are 
positively regulated by ESR1 in tumours (Figure 1A). Conversely, 
genes that are negatively regulated by ESR1 are enriched among 
the genes that are repressed on oestrogen stimulation, again 
entirely in keeping with expectations. We next examined how 
the ESR1 regulon responds to FGF10 stimulation (on a back-
ground of oestrogen signalling). Compared with the oestrogen 
treatment alone, the oestrogen plus FGF10 treatment leads to a 
downregulation of ESR1 positive targets, whereas ESR1-negative 
target genes are upregulated (Figure 1B). This strongly suggests 
that FGFR2 signalling counteracts ESR1 signalling in these cells. 
To confirm this, we transfected siRNA against ESR1 into MCF-7 
cells and tested the effect on the gene expression profiles. The 
direction of the response was the same as that for FGF10 signal-
ling (Figure 1C), in keeping with the notion that FGF10 inhibits 
ESR1 signalling.
In addition to the induction described above (Exp1), we have 
previously established two additional model systems to exam-
ine FGFR2 signalling in MCF-7 cells (30): cells overexpressing 
the FGFR2 kinase domain, which can be activated by a small-
molecule crosslinker (AP20187; Exp2), and cells overexpressing 
full-length FGFR2b from a Tet-inducible promoter (Exp3). In all 
three of these systems, we find that FGFR2 signalling represses 
the ESR1 regulon (Figure 1D–F), with cells overexpressing FGFR2 
showing a stronger response after 24 h (Supplementary Figure 2, 
available at Carcinogenesis Online). Our results demonstrate that 
the effect is likely to be mediated by FGFR2 and not through 
other receptors potentially activated by FGF10.
To confirm that FGFR2 is required in this response, we next 
examined the effect of reducing FGFR2 expression on the oes-
trogen response. We transfected MCF-7 cells with siRNA against 
FGFR2 before cell synchronization and subsequent stimulation 
of FGFR2 signalling (on a background of oestrogen signalling). 
Knock-down of FGFR2 reduced FGFR2 mRNA and protein levels 
in siFGFR2-transfected versus untransfected cells (Figure 2A). IL8 
is one of the genes most strongly induced upon FGFR2 stimu-
lation and we demonstrated that FGF10-induced IL8 mRNA 
expression is reduced in siFGFR2-transfected cells (Figure  2B). 
Microarray analysis of gene expression followed by GSEA was 
Figure 1. Response of the ESR1 regulon in MCF-7 cells to oestrogen and FGFR2 signalling. The top panel in each plot shows the response of all genes on the microarray, 
with the y-axis representing the fold change in gene expression to any given stimulus (phenotype), as shown. The bar beneath the phenotype shows red marks for 
activated and blue marks for repressed members of the ESR1 regulon. The GSEA plots show the running enrichment score for positive (red line) and negative (blue line) 
targets in the ESR1 regulon in MCF-7 cells. The x-axis applies to all three panels and lists all genes ranked by the phenotype. (A–C) MCF-7 cells were stimulated with (A) 
1 nM E2 for 6 h, (B) 1 nM E2 plus 100 ng/ml FGF10 for 6 h and (C) 50 nM siRNA directed against ESR1 for 24 h. (D) Cartoon of two additional FGFR2 signalling model systems. 
MCF-7 cells stably overexpressing the FGFR2 kinase domain, which can be activated by a small-molecule crosslinker (AP20187) (Exp2) and MCF-7 cells overexpressing 
full-length FGFR2b from a Tet-inducible promoter (Exp3) are depicted. (D and E) GSEA plots after cell stimulation for Exp2 (D) and Exp3 (E), after 6 h.
Copyedited by: SU
 at U
niversity of Cam
bridge on June 21, 2016
http://carcin.oxfordjournals.org/
D
ow
nloaded from
 
T.M.Campbell et al. | 5
carried out as described for Exp1–3 above. While knocking down 
FGFR2 had no effect on the ESR1 regulon response to oestrogen 
treatment (Figure 2C and E), the FGFR2 knock-down significantly 
dampened the response of the ESR1 regulon to FGF10 treatment 
(Figure 2D and F). In the untransfected cells, FGF10 reversed the 
response to oestrogen and genes that are activated by oestro-
gen (shown in a red line in Figure 2C and E) are now repressed 
(Figure 2D). After siFGFR2 transfection, this reversal is much less 
pronounced (Figure 2F). This suggests that the negative effects 
of FGF10 stimulation on oestrogen signalling in MCF-7 cells are 
mediated via FGFR2. This effect was not detected in a simple 
analysis of differential gene expression. Our results highlight 
the power of a network-based analysis to dissect complex tran-
scriptional responses.
To ensure that the effects are not specific to MCF-7 cells, 
we expanded our analysis of gene expression changes after 
FGFR2 signalling to include additional ER+ cell lines: MCF-7, 
T47D, ZR751, SUM52PE and BT474. First, we assessed the levels 
of FGFR2 protein expression in these cell lines and found that 
expression levels varied greatly (Figure 3A): the lowest expres-
sion was found in BT474 cells which have hardly detectable 
levels of FGFR2, with higher expression seen in MCF-7, ZR751 
and T47D cells. Highest expression was in SUM52PE cells, 
which carry an amplification of the FGFR2 locus (39). Following 
oestrogen-starvation, all cell lines were stimulated with oes-
trogen and oestrogen plus FGF10. Assaying IL8 mRNA by qRT-
PCR indicated that the response to FGF10 was proportional to 
FGFR2 expression (Figure 3B and C). FGF10 is the most potent 
agonist of FGFR2 and is the relevant FGFR2 ligand for breast epi-
thelial cells (24,25). It is specific for the FGFR2IIIb isoform, and 
qRT-PCR confirmed that only the FGFR2IIIb isoform is expressed 
in ER+ epithelial breast cancer cells (Figure  3D). Next, we car-
ried out a microarray analysis of gene expression in response 
to FGF10 treatment. Of note, in BT474 cells only a very small 
number of genes responded to FGF10 stimulation. Previous work 
suggested that FGF10 can also interact weakly with the FGFR1 
receptor (40,41), which is expressed in BT474 cells (Figure 3A). 
However, the very small response indicates that the effect is 
negligible in these cells and that FGF10 signals predominantly 
through FGFR2. The unresponsiveness of BT474 cells is visu-
alized in Supplementary Figure  3, available at Carcinogenesis 
Online, showing that there is only a small number of shared 
differentially expressed genes between BT474 and the other ER+ 
breast cancer cell lines in a genome-wide analysis. BT474 cells 
can therefore serve as a negative control in our experiments. In 
contrast, the other four cell lines displayed a large number of 
concordant changes in gene expression after FGFR2 activation 
(Supplementary Figure 3, available at Carcinogenesis Online).
Figure 2. Knocking down FGFR2 dampens ESR1 regulon repression in MCF-7 cells. Relative mRNA expression of FGFR2 (A) and IL8 (B) in MCF-7 cells following cell syn-
chronization and stimulation of oestrogen/FGF10 signalling [oestrogen-starvation for three consecutive days followed by a further 6 h oestrogen-starvation (starved) 
or treatment with either 1 nM E2 (E2) or 1 nM E2 plus 100 ng/ml FGF10 (E2 + FGF10) for 6 h]. CTL: control condition; siFGFR2: cells transfected with siRNA against FGFR2 
for a period of 24 h prior to cell synchronization and stimulation of oestrogen/FGF10 signalling. All data were normalized to DGUOK expression [n = 10, two separate 
experiments, P < 0.001 (***), ns (not significant), one-way ANOVA and SNK correction, error bars = SEM]. Inset: representative western immunoblots showing expression 
of FGFR2 and β-actin proteins in MCF-7 cells following transfection with scrambled siRNA (siScrambled) or siRNA directed against FGFR2 (siFGFR2), and cell synchro-
nization (n = 3 for both blots). (C–F) GSEA plots showing the degree of enrichment for positive and negative targets in the ESR1 regulon in MCF-7 cells that have either 
been transfected with a scrambled siRNA sequence (C and D) or siRNA directed against FGFR2 (E and F), following treatment with 1 nM E2 for 6 h (C and E) and 1 nM E2 
plus 100 ng/ml FGF10 for 6 h (D and F).
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Figure 3. FGFR2 expression and activity in ER+ breast cancer cells. (A) Representative western immunoblots showing expression of FGFR2, FGFR1, ESR1 and β-actin 
proteins in ER+ human breast cancer cell lines (n = 3 for all blots). (B) Relative mRNA expression of IL8 in five different ER+ human breast cancer cell lines (MCF-7, T47D, 
ZR751, SUM52PE and BT474) following cell synchronization and stimulation of oestrogen/FGF10 signalling [oestrogen-starvation for three consecutive days followed 
by a further 6 h oestrogen-starvation (starved) or treatment with either 1 nM E2 (E2) or 1 nM E2 plus 100 ng/ml FGF10 (E2 + FGF10) for 6 h]. All data were normalized to 
DGUOK expression [n = 10, two separate experiments, P < 0.001 (***), ns (not significant), one-way ANOVA and SNK correction, error bars = SEM]. (C) Correlation plot 
showing the relationship between FGFR2 protein level [determined by densitometry analysis of the FGFR2 western immunoblots shown in (A)] and IL8 mRNA expres-
sion following FGF10 stimulation [shown in (B)] for the five ER+ human breast cancer cell lines. (D) Relative mRNA expression of the FGFR2IIIb (b) and FGFR2IIIc (c) 
isoforms in the five ER+ human breast cancer cell lines. HMF3S, human mammary fibroblast cell line used as a positive control for the FGFR2IIIc primers. HMF3S is a 
mesenchymal cell line, all others are epithelial. Expression levels in SUM52PE cells are shown on a different scale because the FGFR2 locus is amplified in this cell line. 
All data were normalized to DGUOK expression (n = 10, two separate experiments, error bars = SEM).
Figure 4. Effect of E2 and FGF10 on the ESR1 regulon is consistent across ER+ cell lines. GSEA plots showing the degree of enrichment for positive and negative targets 
in the ESR1 regulon in five different ER+ human breast cancer cell lines (MCF-7, T47D, ZR751, SUM52PE and BT474) following treatment with either 1 nM E2 (E2) or 1 nM 
E2 plus 100 ng/ml FGF10 (E2 + FGF10) for 6 h.
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Two-tailed GSEA was carried out for the ESR1 regulon after 
the two different treatments (oestrogen alone and oestro-
gen plus FGF10) in the five ER+ cell lines. For T47D and ZR751 
cells, results are very similar to the response seen in MCF-7s 
(Figure 4). In contrast, BT474 cells, which have low FGFR2 expres-
sion, display a very low enrichment score for FGF10-repressed 
genes in the ESR1 regulon. Furthermore, there is a lower oes-
trogen response in SUM52PE cells, which express high levels 
of FGFR2. Presumably, the high levels of FGFR2 expression lead 
to some constitutive FGFR2 signalling, even in the absence of 
FGF10 ligand. These results provide further evidence that FGFR2 
signalling counteracts cell activation by oestrogen signalling.
Motif analysis of oestrogen-responsive genes
As yet, we do not understand the molecular mechanism by 
which FGFR2 exerts its effect on gene expression. We asked 
whether distinct regulatory elements could be detected at the 
ESR1 binding sites of activated and repressed genes. Using the 
HOMER motif discovery algorithm, we found that very similar 
motifs were identified near ESR1 binding sites at oestrogen-
activated and oestrogen-repressed genes. As expected, these 
included the oestrogen response element itself as well as 
FOXA1, AP2 and FOS/JUN binding sites. The P-value for enrich-
ment for the oestrogen response element motif was somewhat 
higher in positively regulated genes, but otherwise no consist-
ent differences were found when varying the motif finding 
parameters (Supplementary Table  4, available at Carcinogenesis 
Online). Similar motifs were also identified when searching for 
de novo motifs (data not shown).
Risk SNPs reduce FGFR2 expression within a 
silencer context
Exposure to oestrogen has long been known to be one of the 
key risk factors for breast cancer development, and anti-oes-
trogen therapies are a fundamental current strategy for breast 
cancer prevention and treatment (42–44). As FGFR2 reduces 
the potency of oestrogen activation, we hypothesized that the 
risk variants in the FGFR2 locus should reduce transcriptional 
Figure 5. Risk SNPs reduce FGFR2 expression within a silencer context. (A) Schematic depiction of the start of the FGFR2 gene, showing the location of the cloned FGFR2 
promoter and two response elements (RE1 and RE2) containing the three SNPs in intron 2. (B) Schematic depiction of the reporter constructs used in the luciferase 
reporter assays. The full-length FGFR2 promoter was cloned into the multiple cloning site of a pGL3-Basic Luciferase Reporter Vector in order to generate a reporter 
construct in which the luciferase gene is transcribed from the FGFR2 promoter. The putative FGFR2 regulatory elements (RE1 and RE2) containing the risk SNP vari-
ants were then cloned upstream of the FGFR2 promoter. (C and D) Luciferase luminescence in MCF-7 cells 24 h post-transfection of reporter constructs, normalized to 
β-galactosidase expression. pGL3-b: pGL3-Basic vector; pGL3-FGFR2: pGL3-Basic vector + FGFR2 promoter; pGL3-FGFR2-RE1/2: pGL3-Basic vector + FGFR2 promoter + 
regulatory element 1/2; n: non-risk SNP variant; r: risk SNP variant [n = 9, three separate experiments, P < 0.05 (*), P < 0.001 (***), ns (not significant), one-way ANOVA and 
SNK correction, error bars = SEM]. (E) Key showing which risk SNP variants are present in the regulatory element of each reporter construct.
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activation. rs2981578, rs35054928 and rs45631563 have previ-
ously been identified as the most likely causative variants in 
each of the three independent, correlated highly associated 
variants defined through genetic mapping of the FGFR2 risk 
locus (20). To assess the role of these risk SNPs (Supplementary 
Table  5, available at Carcinogenesis Online) on FGFR2 expres-
sion, we first generated a luciferase reporter construct in 
which the luciferase gene is transcribed from the FGFR2 pro-
moter. Upstream of this we cloned the two putative FGFR2 
regulatory elements, RE1 and RE2 (Supplementary Figure  4, 
available at Carcinogenesis Online), and tested the resultant 
constructs in transient transfection assays in MCF-7 cells. We 
found that both RE1 (chr10: 123 339 661 to 123 340 461; 801 bp) 
and RE2 (chr10: 123 349160 to 123 349 998; 839 bp) function 
as silencer elements, reducing transcription from the FGFR2 
promoter 1.9- and 2.0-fold, respectively (Figure 5). In keeping 
with the proposed silencer function, we note that the tran-
scriptional repressors YY1, SIN3A and HDAC2 (Supplementary 
Figure  4, available at Carcinogenesis Online) bind within 
RE1. In the presence of the two risk variants at rs2981578 
and rs35054928 in RE1, transcription is further reduced by 
21%. Similarly, in the presence of the single risk variant at 
rs45631563 in RE2, transcription is 22% lower compared with 
the RE2 construct containing the non-risk allele. Thus, the 
risk variants of all three SNPs increase silencer activity of the 
regulatory elements.
Discussion
Here, we demonstrate that in breast cancer cell lines FGFR2 
signalling is able to oppose the effect of oestrogen signalling 
(Figure 6). This repression occurs independent of the mechanism 
of FGFR2 activation, either via its ligand, FGF10, or via dimeri-
zation of the FGFR2 kinase domain. Furthermore, we find that 
the response is proportional to the level of FGFR2 expression, 
with higher expression leading to a stronger induction of known 
response genes such as IL8 and more pronounced inhibition of 
the oestrogen response (in SUM52PE cells). Conversely, depletion 
of FGFR2 via siRNA treatment abrogates the suppressive effect 
of FGF10 on the oestrogen regulon. As oestrogen is the key driver 
of ER+ breast cancer, our results suggest that an increase in dis-
ease risk should be associated with reduced FGFR2 expression.
Consistent with this we find that all three risk variants 
within the FGFR2 locus act to reduce transcriptional activation 
at the FGFR2 promoter. The effect of rs2981578 was significantly 
stronger than that of rs35054928. These results are in keeping 
with the findings (20) that in MCF-7 cells there is an 8.5-fold 
increase in FOXA1 binding at the risk allele of rs2981578, whereas 
the difference in nuclear protein (E2F1) binding between the two 
alleles at rs35054928 was only 2.4- to 3.8-fold. Due to genetic 
linkage, the two risk SNPs are co-inherited, conferring reduced 
FGFR2 expression. Our previous analysis of a multimerized 
rs2981578 site had suggested that the disease-associated allele 
Figure 6. The relationship between FGFR2 signalling and the oestrogen response in ER+ breast cancer cells. Diagram showing how the data presented in this study sup-
ports the hypothesis that FGFR2 signalling has an inhibitory effect on oestrogen signalling. Presented are three GSEA plots showing the response of the ESR1 regulon 
to E2 treatment, E2 plus FGF10 treatment and knock-down of ESR1 with siRNA. Above each GSEA plot is a schematic representing how we propose the positively and 
negatively regulated genes in the ESR1 regulon respond to the various cell treatments. Reduced FGFR2 expression as a result of the presence of risk SNPs in the second 
intron of the FGFR2 gene would result in an increase in the oestrogen response in this context. 
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increases FGFR2 transcription (21). However, in these earlier 
experiments, the multimerized rs2981578 site was not tested in 
its normal chromosomal context as part of a larger regulatory 
element. We now demonstrate that this element functions as 
a silencer element. Therefore, these apparently contradictory 
findings can easily be reconciled. In line with our earlier studies, 
we propose that FOXA1 binds more strongly to the risk allele 
of rs2981578, increasing chromatin accessibility (20) and allow-
ing access to transcriptional repressors such as YY1, SIN3A and 
HDAC2, leading to a reduction in FGFR2 promoter activity. The 
third risk variant, rs45631563, is relatively infrequent (3%), thus 
making a smaller contribution to overall risk, but also repressed 
FGFR2 transcription.
The observation that risk variants reduce FGFR2 expres-
sion is consistent with a study that assayed purified, cultured 
mammary epithelial cells and reported that the presence of 
the rs2981578 risk allele led to lower FGFR2 expression (23). 
Another study reported lower levels of FGFR2 mRNA and pro-
tein expression in tumour compared with normal breast tis-
sue (18). This study examined a small number of patients (21 
matched tumour-normal pairs and 10 tumour samples without 
corresponding normal tissue), but samples were microdissected 
to maximize any detectable differences. In contrast, a recent 
eQTL study of normal breast tissue failed to see an association 
between the risk alleles and FGFR2 expression (45), but in this 
study, tissue was not microdissected. It is not clear how this 
might fit with experimental data that suggest FGFR2 is impor-
tant in increased branching during mammary gland develop-
ment and in the generation of breast tumour-initiating cells 
(13–17): it is likely that FGFR2 may play distinct roles at different 
stages of breast development.
Our findings of a link between FGFR2 signalling and oestro-
gen responsiveness are also supported by epidemiologic studies 
(46), which have reported an interaction between hormone ther-
apy and FGFR2 genotype. The SNP identified in this study was 
independent from the SNPs most strongly associated with breast 
cancer risk in genetic fine mapping studies (20), for which a hor-
mone interaction could only be detected in some cohorts (46–48).
Most receptor tyrosine kinases are thought to be able to act 
as oncogenes if deregulated. Indeed, FGFR1 is frequently ampli-
fied or mutated in prostate adenocarcinoma (23%), lung squa-
mous carcinoma (23%) and breast cancer (14.3%) (TCGA), and 
FGFR inhibitors are being trialled clinically. Yet our results sug-
gest that FGFR2 plays a suppressive role in breast cancer. In sup-
port of this, genomic studies found that FGFR2 amplifications 
(1.8%) or mutations (1.3 %) are relatively rare in breast cancer 
(cBioportal, TCGA). The results we present here suggest that 
FGFR inhibitors may augment the risk of breast cancer develop-
ment and this should be borne in mind when selecting patient 
groups for treatment with pan-FGFR inhibitors.
In conclusion, our analysis of FGFR2 signalling and the effect 
of breast cancer risk variants suggest that the role of FGFR2 ger-
mline variants in breast cancer risk may be linked to reducing 
a cell’s ability to respond to oestrogen activation. The role of 
FGFR2 in breast cancer risk may therefore be distinct from the 
role normally associated with FGFRs in tumour progression. The 
molecular mechanism we propose establishes a link between 
the inherited risk for breast cancer conferred by germline vari-
ation in FGFR2 and environmental effects (oestrogen exposure).
Supplementary material
Supplementary Tables 1–5 and Figures 1–4 can be found at 
http://carcin.oxfordjournals.org/
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